Protagonist Therapeutics, Inc (PTGX) stock
PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$124.67−0.16 (-0.13%)
Close on Nov 17, 2026Market cap $8.07BP/E 121.0Yield –
Protagonist Therapeutics cash
Cash and short-term investments held at the end of each period.
Protagonist Therapeutics's cash was $782.58M at Jun 30, 2026. For fiscal 2025 it was $567.36M, up 35.4% from the year before. Over ten years it grew 63.9% a year on average. The highest annual figure on record is $567.36M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $567.36M | +35.4% |
| FY2024 | Dec 31, 2024 | $419.14M | +22.7% |
| FY2023 | Dec 31, 2023 | $341.62M | +43.8% |
| FY2022 | Dec 31, 2022 | $237.58M | -27.4% |
| FY2021 | Dec 31, 2021 | $327.13M | +6.8% |
| FY2020 | Dec 31, 2020 | $306.27M | +129.5% |
| FY2019 | Dec 31, 2019 | $133.48M | +3.2% |
| FY2018 | Dec 31, 2018 | $129.31M | +21.4% |
| FY2017 | Dec 31, 2017 | $106.49M | +404.8% |
| FY2016 | Dec 31, 2016 | $21.09M | +418.9% |
| FY2015 | Dec 31, 2015 | $4.07M | -56.4% |
| FY2014 | Dec 31, 2014 | $9.33M | +10.3% |
| FY2013 | Dec 31, 2013 | $8.46M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $782.58M | +37.2% |
| Q1 FY2026 | Mar 31, 2026 | $547.79M | -4.6% |
| Q4 FY2025 | Dec 31, 2025 | $567.36M | +35.4% |
| Q3 FY2025 | Sep 30, 2025 | $576.12M | +22.9% |
| Q2 FY2025 | Jun 30, 2025 | $570.47M | +1.1% |
| Q1 FY2025 | Mar 31, 2025 | $574.36M | +78.0% |
| Q4 FY2024 | Dec 31, 2024 | $419.14M | +22.7% |
| Q3 FY2024 | Sep 30, 2024 | $468.72M | +46.1% |
| Q2 FY2024 | Jun 30, 2024 | $564.00M | +80.0% |
| Q1 FY2024 | Mar 31, 2024 | $322.64M | +39.8% |
| Q4 FY2023 | Dec 31, 2023 | $341.62M | +43.8% |
| Q3 FY2023 | Sep 30, 2023 | $320.75M | +19.9% |
| Q2 FY2023 | Jun 30, 2023 | $313.40M | +7.4% |
| Q1 FY2023 | Mar 31, 2023 | $230.76M | -24.4% |
| Q4 FY2022 | Dec 31, 2022 | $237.58M | -27.4% |
| Q3 FY2022 | Sep 30, 2022 | $267.44M | -14.9% |
| Q2 FY2022 | Jun 30, 2022 | $291.89M | -17.6% |
| Q1 FY2022 | Mar 31, 2022 | $305.29M | +11.6% |
| Q4 FY2021 | Dec 31, 2021 | $327.13M | +6.8% |
| Q3 FY2021 | Sep 30, 2021 | $314.30M | +62.0% |
| Q2 FY2021 | Jun 30, 2021 | $354.28M | +69.8% |
| Q1 FY2021 | Mar 31, 2021 | $273.48M | +132.7% |
| Q4 FY2020 | Dec 31, 2020 | $306.27M | +129.5% |
| Q3 FY2020 | Sep 30, 2020 | $193.97M | +40.9% |
| Q2 FY2020 | Jun 30, 2020 | $208.67M | +65.5% |
| Q1 FY2020 | Mar 31, 2020 | $117.51M | +67.7% |
| Q4 FY2019 | Dec 31, 2019 | $133.48M | +3.2% |
| Q3 FY2019 | Sep 30, 2019 | $137.69M | +57.5% |
| Q2 FY2019 | Jun 30, 2019 | $126.10M | +97.5% |
| Q1 FY2019 | Mar 31, 2019 | $70.08M | +0.7% |
| Q4 FY2018 | Dec 31, 2018 | $129.31M | +21.4% |
| Q3 FY2018 | Sep 30, 2018 | $87.43M | +73.5% |
| Q2 FY2018 | Jun 30, 2018 | $63.86M | +516.2% |
| Q1 FY2018 | Mar 31, 2018 | $69.58M | +631.1% |
| Q4 FY2017 | Dec 31, 2017 | $106.49M | +404.8% |
| Q3 FY2017 | Sep 30, 2017 | $50.40M | -47.5% |
| Q2 FY2017 | Jun 30, 2017 | $10.37M | – |
| Q1 FY2017 | Mar 31, 2017 | $9.52M | – |
| Q4 FY2016 | Dec 31, 2016 | $21.09M | – |
| Q3 FY2016 | Sep 30, 2016 | $96.02M | – |
See a number that looks wrong?